Parviz Hanjani

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller, Virginia L. Filiaci, Robert S. Mannel et al. · Journal of Clinical Oncology · 2020 · 313 citations · Full text

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy et al. · Journal of Clinical Oncology · 2011 · 312 citations · Full text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Stephen C. Rubin et al. · Gynecologic Oncology · 2005 · 243 citations

Phase Ii Trial, Medicine, Cancer Management +8

Adverse psychologic consequences of positive cYtologic cervical screening

Caryn Lerman, Suzanne M. Miller, Ruth Scarborough et al. · American Journal of Obstetrics and Gynecology · 1991 · 204 citations

Cervical Cancer Management, Cervical Cancer Screening, Cervical Cancer +11

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

David S. Miller, John A. Blessing, Carolyn Krasner et al. · Journal of Clinical Oncology · 2009 · 182 citations · Full text